Item 1.01 Entry into a Material Definitive Agreement.

Second Amendment to Agreement and Plan of Merger

As previously disclosed, on May 17, 2020, Neurotrope, Inc., a Nevada corporation ("Neurotrope"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Petros Pharmaceuticals, Inc., a Delaware corporation formed for the purposes of effecting transactions contemplated by the Merger Agreement ("Petros"), PM Merger Sub 1, LLC, a Delaware limited liability company and a wholly-owned subsidiary of Petros ("Merger Sub 1"), PN Merger Sub 2, Inc., a Delaware corporation and a wholly-owned subsidiary of Petros ("Merger Sub 2"), and Metuchen Pharmaceuticals LLC, a Delaware limited liability company ("Metuchen"). The Merger Agreement provides for (1) the merger of Merger Sub 1, with and into Metuchen, with Metuchen surviving as a wholly-owned subsidiary of Petros (the "Metuchen Merger") and (2) the merger of Merger Sub 2 with and into Neurotrope, with Neurotrope surviving as a wholly-owned subsidiary of Petros (the "Neurotrope Merger" and together with the Metuchen Merger, the "Mergers"). On July 23, 2020, Neurotrope, Petros, Merger Sub 1, Merger Sub 2 and Metuchen entered into a First Amendment to the Merger Agreement (the "First Amendment") which provided, among other things, that the aggregate number of shares of Petros common stock to be issued to the Metuchen securityholders in the Mergers was 82,587,877. In addition, upon the achievement of certain targets set forth in the First Amendment, Petros agreed to deposit earnout payments with the exchange agent for distribution to each unitholder of Metuchen prior to the closing of the Metuchen Merger in accordance with such unitholder's earnout pro rata percentage.

On September 30, 2020, Neurotrope, Petros, Merger Sub 1, Merger Sub 2 and Metuchen entered into a Second Amendment to the Merger Agreement (the "Second Amendment") which provides, among other things, that the aggregate number of shares of Petros common stock to be issued to the Metuchen securityholders in the Mergers is 24,748,051. In addition, upon the achievement of certain targets set forth in the Second Amendment, Petros will deposit earnout payments (the "Earnout Payments") with the exchange agent for distribution to each unitholder of Metuchen prior to the closing of the Mergers in accordance with such unitholder's earnout pro rata percentage (as defined in the Second Amendment) as follows:





    ·   If at any time following the closing of the Mergers and prior to the one
        year anniversary of the closing of the Mergers, the closing price per
        share of Petros common stock is:




          o   (i) greater than or equal to $1.60 for a period of twenty (20)
              trading days during any thirty (30) consecutive trading day period,
              then the earnout payment will be equal to 5,000,000 shares of Petros
              common stock ("First Period Initial Milestone Earnout Payment");




          o   (ii) greater than or equal to $2.00 for a period of twenty (20)
              trading days during any thirty (30) consecutive trading day period,
              then the earnout payment will be equal to 5,000,000 shares of Petros
              common stock (the "First Period Second Milestone Earnout Payment");




          o   (iii) greater than or equal to $2.60 for a period of twenty (20)
              trading days during any thirty (30) consecutive trading day period,
              then the earnout payment will be equal to 5,000,000 shares of Petros
              common stock (the "First Period Third Milestone Earnout Payment");
              and




          o   (iv) greater than or equal to $3.00 for a period of twenty (20)
              trading days during any thirty (30) consecutive trading day period,
              then the earnout payment will be equal to 5,000,000 shares of Petros
              common stock (the "First Period Final Milestone Earnout Payment").




    ·   If at any time within the twelve (12) month period following the one year
        anniversary of the closing of the Mergers, the closing price per share of
        Petros common stock is:








          o   (i) greater than or equal to $2.00 for a period of twenty (20)
              trading days during any thirty (30) consecutive trading day period,
              then the earnout payment will be equal to 5,000,000 shares of Petros
              common stock ("Second Period Initial Milestone Earnout Payment" and
              together with the First Period Initial Milestone Earnout Payment,
              the "First Milestone Earnout Payment);




          o   (ii) greater than or equal to $2.50 for a period of twenty (20)
              trading days during any thirty (30) consecutive trading day period,
              then the earnout payment will be equal to 5,000,000 shares of Petros
              common stock (the "Second Period Second Milestone Earnout Payment"
              and together with the First Period Second Milestone Earnout Payment,
              the "Second Milestone Earnout Payment);




          o   (iii) greater than or equal to $3.25 for a period of twenty (20)
              trading days during any thirty (30) consecutive trading day period,
              then the earnout payment will be equal to 5,000,000 shares of Petros
              common stock (the "Second Period Third Milestone Earnout Payment"
              and together with the First Period Third Milestone Earnout Payment,
              the "Third Milestone Earnout Payment); and




          o   (iv) greater than or equal to $3.75 for a period of twenty (20)
              trading days during any thirty (30) consecutive trading day period,
              then the earnout payment will be equal to 5,000,000 shares of Petros
              common stock (the "Second Period Final Milestone Earnout Payment"
              and together with the First Period Final Milestone Earnout Payment,
              the "Final Milestone Earnout Payment." The First Milestone Earnout
              Payment, the Second Milestone Earnout Payment, the Third Milestone
              Earnout Payment and the Final Milestone Earnout Payment are
              collectively referred to herein as the "Milestone Earnout Payments"
              and individually as a "Milestone Earnout Payment").



Each Milestone Earnout Payment is only achievable and payable one time and upon achievement of such Milestone Earnout Payment, there will be no further payments with respect to such Milestone Earnout Payment. Further, upon achievement of a Milestone Earnout Payment in the First Period, the corresponding milestone for the Second Period will not be achievable. In no event will the sum of the First Milestone Earnout Payment, the Second Milestone Earnout Payment, the Third Milestone Earnout Payment and the Final Milestone Earnout Payment be greater than 20,000,000 shares of Petros common stock.





·   In addition to the Milestone Earnout Payments, Metuchen equity holders will
    have the opportunity to receive the following during the period ending on the
    second anniversary of the closing of the Mergers if:




          o   (a) either (i) Petros' Market Capitalization (as defined in the
              Second Amendment) is greater than or equal to $250,000,000 for a
              period of twenty (20) trading days during any thirty (30)
              consecutive trading day period with a closing price per share of
              Petros common stock of no less than $3.50 on each such trading day
              or (ii) Petros receives aggregate gross proceeds of at least
              $25,000,000 in an offering (or series of offerings within a sixty
              (60) calendar day period) of Petros common stock with a price per
              share of Petros common stock sold equal to no less than $3.50 in
              each offering (or series of offerings) and where Petros has a Market
              Capitalization immediately prior to each such offering (or series of
              offerings) equal to at least $250,000,000, then the Earnout Payment
              shall be equal to 10,000,000 shares of Petros common stock (the
              "Initial Market Capitalization/Gross Proceeds Earnout Payment");

          o   (b) either (i) Petros' Market Capitalization is greater than or
              equal to $300,000,000 for a period of twenty (20) trading days
              during any thirty (30) consecutive trading day period with a closing
              price per share of Petros common stock of no less than $3.75 on each
              such trading day or (ii) Petros receives aggregate gross proceeds of
              at least $30,000,000 in an offering (or series of offerings within a
              sixty (60) calendar day period) of Petros common stock with a price
              per share of Petros common stock sold equal to no less than $3.75 in
              each offering (or series of offerings) and where Petros has a Market
              Capitalization immediately prior to each such offering (or series of
              offerings) equal to at least $300,000,000, then the Earnout Payment
              shall be equal to 10,000,000 shares of Petros common stock, (the
              "Second Market Capitalization/Gross Proceeds Earnout Payment");








          o   (c) either (i) Petros' Market Capitalization is greater than or
              equal to $400,000,000 for a period of twenty (20) trading days
              during any thirty (30) consecutive trading day period with a closing
              price per share of Petros common stock of no less than $4.50 on each
              such trading day or (ii) Petros receives aggregate gross proceeds of
              at least $40,000,000 in an offering (or series of offerings within a
              sixty (60) calendar day period) of Petros common stock with a price
              per share of Petros common stock sold equal to no less than $4.50 in
              each offering (or series of offerings) and where Petros has a Market
              Capitalization immediately prior to each such offering (or series of
              offerings) equal to at least $400,000,000, then the Earnout Payment
              shall be equal to 15,000,000 shares of Petros common stock (the
              "Third Market Capitalization/Gross Proceeds Earnout Payment"); and

          o   (d) either (i) Petros' Market Capitalization is greater than or
              equal to $500,000,000 for a period of twenty (20) trading days
              during any thirty (30) consecutive trading day period with a closing
              price per share of Petros common stock of no less than $4.75 on each
              such trading day or (ii) Petros receives aggregate gross proceeds of
              at least $50,000,000 in an offering (or series of offerings within a
              sixty (60) calendar day period) of Petros common stock with a price
              per share of Petros common stock sold equal to no less than $4.75 in
              each offering (or series of offerings) and where Petros has a Market
              Capitalization immediately prior to each such offering (or series of
              offerings) equal to at least $500,000,000, then the Earnout Payment
              shall be equal to 16,160,451 shares of Petros common stock, (the
              "Final Market Capitalization/Gross Proceeds Earnout Payment." The
              Initial Market Capitalization/Gross Proceeds Earnout Payment, the
              Second Market Capitalization/Gross Proceeds Earnout Payment, the
              Third Market Capitalization/Gross Proceeds Earnout Payment and the
              Final Market Capitalization/Gross Proceeds Earnout Payment are
              collectively referred to herein as the "Market Capitalization/Gross
              Proceeds Earnout Payments" and individually as a "Market
              Capitalization/Gross Proceeds Earnout Payment").


Each Market Capitalization/Gross Proceeds Earnout Payment will only be achievable and payable one time and upon achievement of such Market Capitalization/Gross Proceeds Earnout Payment, there will be no further payments with respect to such Market Capitalization/Gross Proceeds Earnout Payment. In no event will the sum of the Initial Market Capitalization/Gross Proceeds Earnout Payment, the Second Market Capitalization/Gross Proceeds Earnout Payment, the Third Market Capitalization/Gross Proceeds Earnout Payment and the Final Market Capitalization/Gross Proceeds Earnout Payment be greater than 51,160,451 shares of Petros common stock. Further, in no event will the sum of the Milestone Earnout Payments and the Market Capitalization/Gross Proceeds Earnout Payments be greater than 71,160,451 shares of Petros common stock.

Each reference to share prices and Petros common stock will be subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transaction of the Petros common stock that occur after the date of the Merger Agreement.

A portion of the Earnout Payments will be allocated to holders of Metuchen warrants on a pro rata basis, such portion to be equal to a fraction (a) the numerator of which is (i) 8,730,000 minus (ii) the number of shares currently held by the holders of Metuchen warrants divided (b) the denominator of which is 71,160,451. The remaining portion of the Earnout Payments will be distributed to the other holders of Metuchen units on a pro-rata basis.

The Second Amendment also amends and restates Section 6.11 of the Merger Agreement to provide that immediately following the closing of the Mergers, the Petros board of directors will consist of five (5) directors, of which three (3) directors will be designated by Metuchen and two (2) directors will be designated by Neurotrope. In addition, the Second Amendment amends and restates Section 6.11 of the Merger Agreement to remove references to Dr. Charles Ryan being designated as the Chief Executive Officer of Petros.

The Second Amendment additionally amends and restates certain defined terms in the Merger Agreement, including the definition of "Excess Cash" to reduce the amount of cash to be retained by Petros following the Mergers by fifty percent (50%) of any severance, change-in-control payments or similar payment obligations that become due or payable to Dr. Charles Ryan. Excess Cash relates to the amount of cash to be distributed to Neurotrope Bioscience, Inc., a wholly-owned subsidiary of Neurotrope ("Neurotrope Bioscience"), in connection . . .




Item 9.01      Financial Statements and Exhibits



The following exhibits are filed herewith:





(d) Exhibits.



Exhibit No.                                 Description
    2.1         Second Amendment to Agreement and Plan of Merger, dated as of
              September 30, 2020, by and between Petros Pharmaceuticals, Inc., PM
              Merger Sub 1, LLC, PN Merger Sub 2, Inc., Neurotrope, Inc. and Metuchen
              Pharmaceuticals, Inc.
    4.1         Form of the Amended and Restated Series E Warrant
    4.2         Form of the Amended and Restated Series F Warrant
    4.3         Form of the Amended and Restated Series G Warrant
    4.4         Form of the Amended and Restated Series H Warrant
    4.5         Form of Series A Common Stock Warrant (Series E Spin-Off Warrant)
    4.6         Form of Series B Common Stock Warrant (Series F Spin-Off Warrant)
    4.7         Form of Series C Common Stock Warrant (Series G Spin-Off Warrant)
    4.8         Form of Series D Common Stock Warrant (Series H Spin-Of Warrant)
   10.1         Form of Voting Agreement by and between Metuchen and certain
              stockholders of Neurotrope
   10.2         Warrant Amendment Agreement, dated as of September 29, 2020, by and
              between Neurotrope, Inc. and the holders of Series E warrants
   10.3         Warrant Amendment Agreement, dated as of September 29, 2020, by and
              between Neurotrope, Inc. and the holders of Series F warrants
   10.4         Warrant Amendment Agreement, dated as of September 29, 2020, by and
              between Neurotrope, Inc. and the holders of Series G warrants
   10.5         Warrant Amendment Agreement, dated as of September 29, 2020, by and
              between Neurotrope, Inc. and the holders of Series H warrants
    104       Cover Page Interactive Data File (embedded within the Inline XBRL
              document).

© Edgar Online, source Glimpses